Each single-dose sachet contains Fosfomycin Trometamol 3 g.

Icufos-O is a broad-spectrum oral antibacterial formulation containing Fosfomycin Trometamol, specifically designed for the convenient single-dose treatment of uncomplicated urinary tract infections. It exhibits rapid bactericidal activity against susceptible urinary pathogens and helps reduce bacterial adherence to the urinary tract epithelium, thereby promoting effective eradication of infection. The single-dose regimen improves patient compliance while minimizing the duration of antibiotic therapy.

Icufos-O is indicated for the treatment of uncomplicated urinary tract infections (acute cystitis) in women caused by susceptible strains of Escherichia coli and Enterococcus faecalis. It is intended for the management of uncomplicated lower urinary tract infections where treatment with a single oral dose is clinically appropriate.

Fosfomycin exerts its bactericidal action by irreversibly inhibiting the enzyme enolpyruvyl transferase, an essential enzyme involved in the early stages of bacterial cell wall synthesis. This inhibition prevents the formation of bacterial cell walls, resulting in bacterial death. Additionally, Fosfomycin reduces the adherence of bacteria to uroepithelial cells, thereby helping prevent bacterial colonization and facilitating the resolution of urinary tract infections.

The recommended dosage for women aged 18 years and older with uncomplicated urinary tract infection (acute cystitis) is one single-dose sachet of Icufos-O. The contents of the sachet should be completely dissolved in water before administration and should never be consumed in dry form. Icufos-O may be taken with or without food or as directed by the treating physician.

Icufos-O is contraindicated in patients with known hypersensitivity to Fosfomycin or any component of the formulation. It is also contraindicated in patients with severe renal insufficiency (creatinine clearance below 10 mL/min) and in patients undergoing haemodialysis.